MK-8591A
Total Payments
$7.9M
Transactions
2,598
Doctors
40
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $7.4M | 2,546 | 36 |
| 2019 | $79,270 | 47 | 6 |
| 2018 | $331,150 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,225 | 98.8% |
| Consulting Fee | $46,689 | 35 | 0.6% |
| Travel and Lodging | $37,566 | 158 | 0.5% |
| Food and Beverage | $10,886 | 179 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75.00 | 1 | 0.0% |
Payments by Type
Research
$7.8M
2,225 transactions
General
$95,216
373 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF | Merck Sharp & Dohme Corporation | $3.9M | 0 |
| A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy | Merck Sharp & Dohme Corporation | $1.4M | 0 |
| Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir Once-Daily in HIV-1 Infected Treatment-Na ve Participants | Merck Sharp & Dohme Corporation | $1.1M | 0 |
| An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Three Experimental Presentations of the Fixed Dosed Combination of Doravirine,Islatravir MK-8591A in Healthy Participants | Merck Sharp & Dohme Corporation | $657,525 | 0 |
| An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and RelativeBioavailability of Two Formulations of MK-8591A and the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of MK-8951A in Healthy Participants | Merck Sharp & Dohme Corporation | $345,333 | 0 |
| A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir ISL, Doravirine DOR, and Doravirine,Islatravir DOR,ISL, Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR,ISL. | Merck Sharp & Dohme Corporation | $202,283 | 0 |
| A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine,Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Na ve, are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg | Merck Sharp & Dohme Corporation | $52,505 | 0 |
| A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral-Activity, and Pharmacokinetics of MK 8591 Given in Combination with Doravirine DOR and Lamivudine 3TC in HIV-1-Infected Treatment-Na ve Adults | Merck Sharp & Dohme Corporation | $4,311 | 0 |
| A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low-Risk for HIV-1 Infection | Merck Sharp & Dohme Corporation | $138.93 | 0 |
Top Doctors Receiving Payments for MK-8591A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $7.8M | 2,225 |
| Princy Kumar | Infectious Disease | Washington, DC | $8,891 | 12 |
| , M.D | Internal Medicine | New York, NY | $8,881 | 17 |
| , MD | Internal Medicine | Providence, RI | $6,950 | 2 |
| , MD | Hematology & Oncology | San Francisco, CA | $5,750 | 6 |
| , MD | Infectious Disease | Chapel Hill, NC | $5,075 | 8 |
| , MD | Infectious Disease | Los Angeles, CA | $4,825 | 2 |
| , MD | Infectious Disease | Cleveland, OH | $3,850 | 6 |
| , M.D | Internal Medicine | Manati, PR | $3,644 | 11 |
| Ricardo Franco | Infectious Disease | Birmingham, AL | $2,676 | 23 |
| , M.D | Family Medicine | San Juan, PR | $2,366 | 9 |
| , M.D | Infectious Disease | New York, NY | $2,361 | 21 |
| , MD | Family Medicine | Savannah, GA | $2,344 | 22 |
| , MD | Infectious Disease | Los Angeles, CA | $2,294 | 1 |
| , MD | Internal Medicine | New Haven, CT | $2,182 | 14 |
| , M.D | Infectious Disease | Hillsborough, NJ | $2,159 | 8 |
| , M.D | Internal Medicine | Philadelphia, PA | $2,000 | 1 |
| , MD | Infectious Disease | Altamonte Springs, FL | $1,811 | 10 |
| , M.D | Internal Medicine | Seattle, WA | $1,796 | 17 |
| , MD | Infectious Disease | Philadelphia, PA | $1,741 | 9 |
| , D.O | Family Medicine | Columbus, GA | $1,681 | 11 |
| , MD | Infectious Disease | Dallas, TX | $1,669 | 10 |
| , MD | Infectious Disease | Augusta, GA | $1,653 | 15 |
| , MD | Internal Medicine | Bellaire, TX | $1,506 | 8 |
| , M.D | Infectious Disease | Decatur, GA | $1,482 | 7 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $7.9M
- Total Doctors 40
- Transactions 2,598
About MK-8591A
MK-8591A is a drug associated with $7.9M in payments to 40 healthcare providers, recorded across 2,598 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $7.4M was paid across 2,546 transactions to 36 doctors.
The most common payment nature for MK-8591A is "Unspecified" ($7.8M, 98.8% of total).
MK-8591A is associated with 9 research studies, including "A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF" ($3.9M).